Eastern Cooperative Oncology Group: Prostatic Neoplasms trials

The registry lists 13 Prostatic Neoplasms studies with Eastern Cooperative Oncology Group as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 5Phase 3 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802CompletedNCT01672905
• Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate CancerWithdrawnNCT00771017Phase 2
• Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate CancerWithdrawnNCT00685633Phase 2
• Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal CancerCompletedNCT00303914
• Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate CancerCompletedNCT00060398Phase 3
• Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate CancerCompletedNCT00027859Phase 3
• Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00005847Phase 2
• PSA Vaccine Therapy in Treating Patients With Advanced Prostate CancerCompletedNCT00003871Phase 2
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerCompletedNCT00003614Phase 2
• Identification of Genes Associated With Cancer in Patients and Siblings Who Have CancerCompletedNCT00003329
• Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate CancerCompletedNCT00002881Phase 3
• Pain Control in Patients With Recurrent or Metastatic Breast or Prostate CancerTerminatedNCT00002668Not applicable
• Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage CancerCompletedNCT00002520Not applicable